The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
== Career == Ho's research has covered emerging areas of nanomedicine and nanodiamond-based drug delivery. Ho and his colleagues were the first to develop nanodiamond platforms for cancer therapy and wound healing, among other areas. Ho and colleagues were the first to demonstrate the translational potential of nanodiamonds as chemotherapeutic delivery agents, specifically towards the treatment of drug-resistant cancers in vivo. This work was published as the Cover Article of the March 9 issue of the journal Science Translational Medicine. Ho is also leading 2 clinical trials to validate nanodiamond-embedded biomaterial devices for wound healing and the prevention of re-infection. He has also developed nanodiamond-functionalized biomaterials for other clinically relevant applications. Ho is also known for his work in the areas of artificial intelligence (AI) and its application towards personalized and precision medicine. His team and colleagues pioneered the field of Augmented AI (CURATE.AI), which mediates model-free and mechanism-independent N-of-1 combination therapy and rapidly accelerated and globally optimized drug development. This has led to multiple clinical trials that have validated the CURATE.AI platform. This AI platform has realized best-in-class medicines for population-wide administration, as well as the unprecedented ability to actionably personalize treatment for the entire duration of care on a patient-specific basis.
After a short introduction from Barbu Petrescu, the mayor of Bucharest and organiser of the rally, Ceaușescu began to speak from the balcony of the Central Committee building, greeting the crowd and thanking the organisers of the rally and the residents of Bucharest. Just over a minute into the speech, a high-pitched scream was heard in the distance. Within seconds, this developed into widespread shouting and screaming, as Ceaușescu looked on while speaking. A few seconds later, he ceased speaking completely, raised his right hand and stared silently at the unfolding chaos. The TV image then shook noticeably and video interference appeared on screen. At that point, Florian Rat, Ceaușescu's bodyguard, appeared and advised Ceaușescu to go inside the building. Censors then cut the live TV feed, but it was too late. The disturbance had already been broadcast, and viewers realised that something highly unusual was occurring. Contrary to many reports, Ceaușescu was not at this point hustled inside the building. Instead, undeterred, he and his wife, Elena, along with other officials, spent almost three minutes trying to understand what was happening and haranguing the confused crowd, some of whom appeared to be trying to leave the area, while others moved towards the Central Committee building. Elena wondered aloud whether there was an earthquake in progress. Ceaușescu repeatedly tapped the microphone, trying to call the attention of the crowd.
=== Clinical trials === Human trials began on January 26, 2021, with 60 volunteers between the ages of 18 and 65 in Toronto. Of these, 15 would receive a placebo and three groups of 15 would receive different doses of the vaccine. The volunteers will be monitored for 13 months. The company said that enough data would be available in May which could result in a Phase 2 clinical testing beginning soon after that, pending regulatory approval. If the results of a subsequent larger human trial are positive, the vaccine could enter a commercialization phase in 2022. The Phase 1 clinical trial lead was Piyush Patel. At the 29 April meeting with the House of Commons, Sorenson estimated that PTX-COVID19-B could be approved by Health Canada by "January or February 2022".
Lemelson-MIT Prize (2014) – known as the "Oscar for inventors", for groundbreaking inventions and dedication to the next generation of scientists. Heinz Award for Technology (2015) – for groundbreaking inventions and advocacy for women in STEM fields. Othmer Gold Medal (2019) – from the Science History Institute. Several honorary doctorate degrees, including from the Icahn School of Medicine at Mount Sinai (2021), University of London Institute Cancer Research (2019), and Utrecht University in the Netherlands (2017). Bhatia has also been honored with:
Sources: en.wikipedia.org
The recall had been ordered after several ships in TF 58 picked up radar contacts 150 miles (240 km) to the west around 10:00. This was the first of the raids from the Japanese carrier forces, with 68 aircraft. TF 58 started launching every fighter it could; by the time they were in the air the Japanese had closed to 70 miles (110 km). However, the Japanese began circling to regroup their formations for the attack. This 10-minute delay proved critical, and the first group of Hellcats met the raid, still at 70 miles (110 km), at 10:36. They were quickly joined by additional groups. Within minutes, 25 Japanese aircraft had been shot down, against the loss of only one U.S. aircraft. The Japanese aircraft that survived were met by other fighters, and 16 more were shot down. Of the 27 aircraft which remained, some made attacks on the picket destroyers USS Yarnall and Stockham but caused no damage. Between three and six bombers broke through to Lee's battleship group and attacked; one bomb hit the main deck of USS South Dakota, killing or injuring over 50 men but failing to disable her. South Dakota was the only American ship damaged in this attack. No aircraft of Ozawa's first wave got through to the American carriers.
== Derivation of Chinese characters == The majority of the Chinese characters used for this purpose are phonosemantic compounds, with part of the character giving a general semantic category and the other part providing a pronunciation, usually based on the international (European) pronunciation. There are four common radicals (the part of the character that gives the semantic category) for these characters:
The Moscow Metro system is well-known for art, murals, mosaics, and chandeliers. This system started operating in 1935 and promptly became the centerpiece of the city's transportation system. Moreover, the system was a Stalinist tactic to awe and reward the population, as well as help them to appreciate Soviet realist art. The system became the prototype for later large-scale Soviet technologies. Lazar Kaganovich headed the system; he designed the subway so that residents would absorb the values and ethos of Stalinist society as they rode. The artwork of the original 13 stations became nationally and internationally known. For example, the Sverdlov Square subway station featured porcelain bas-reliefs depicting the daily life of Soviet people; in addition, the bas-reliefs at the Dynamo Stadium sports complex glorified sports and the physical prowess of the new "Homo Sovieticus" (Soviet man). The metro was heralded as the symbol of a new social order—a sort of communist cathedral of engineering modernity. Soviet workers performed the labor and created the art, but the main engineering designs, routes, and construction plans were handled by specialists recruited from the London Underground. The Britons called for tunneling rather than the "cut-and-cover" technique; preferred escalators over lifts; and designed the routes and the rolling stock. The paranoia of Stalin and the NKVD (Soviet secret police) was evident when the NKVD arrested many British engineers for espionage—that is, for gaining an in-depth knowledge of the city's physical layout.
Sources: en.wikipedia.org
The phase 2 study of LGD-4033 for muscle wasting was finally initiated in November 2016 and was completed with results reported in 2017 and 2018. As of March 2023, LGD-4033 (VK5211) continues to be under development by Viking Therapeutics and continues to be in phase 2 clinical trials for treatment of muscle atrophy and hip fracture.
A technique called osteo-odonto-keratoprosthesis (OOKP) uses a staged operation on those who have developed corneal blindness in which a laminated tooth is transplanted to serve as a support for an artificial optical cylinder.
Some sources state that it does not exist, or at least has never been observed, while other sources assert or imply its existence. Despite this controversy, many properties of diatomic astatine have been predicted; for example, its bond length would be 300±10 pm, dissociation energy <50 kJ/mol, and heat of vaporization (∆vapH) 54.39 kJ/mol. Many values have been predicted for the melting and boiling points of astatine, but only for At2.
Utilizing microorganisms for bioremediation to remove contaminants from our water, soil, and air. Production of complex natural products that are usually extracted from plants but cannot be obtained in sufficient amounts, e.g. drugs of natural origin, such as artemisinin and paclitaxel. Beta-carotene, a substance typically associated with carrots that prevents vitamin A deficiency, is produced by rice that has been modified. Every year, between 250,000 and 500,000 children lose their vision due to vitamin A deficiency, which also significantly raises their chance of dying from infectious infections. As a sustainable and environmentally benign alternative to the fresh roses that perfumers use to create expensive smells, yeast has been created to produce rose oil.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.